Clinical Trials
15 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05389462 2025-05-22
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT05093322 2024-06-07
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT02797977 2023-06-22
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
Phase 1/2 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT02659020 2022-05-09
ANNOUNCE 2
Eli Lilly and Company
Phase 1/2 Completed
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT01574716 2019-08-21
SOURCE
Morphotek
Phase 2 Completed
NCT01325558 2016-07-15
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Phase 1 Completed